S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
NASDAQ:BLCM

Bellicum Pharmaceuticals - BLCM Stock Forecast, Price & News

$1.00
-0.05 (-4.76%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.00
▼
$1.07
50-Day Range
$0.94
▼
$1.25
52-Week Range
$0.93
▼
$2.20
Volume
15,378 shs
Average Volume
29,762 shs
Market Capitalization
$8.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Bellicum Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
400.0% Upside
$5.00 Price Target
Short Interest
Healthy
1.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of Bellicum Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.54) to ($1.13) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

See Top Rated MarketRank™ Stocks Here
BLCM stock logo

About Bellicum Pharmaceuticals (NASDAQ:BLCM) Stock

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BLCM Stock News Headlines

December 8, 2022 | americanbankingnews.com
Bellicum Pharmaceuticals (NASDAQ:BLCM) Receives New Coverage from Analysts at StockNews.com
December 6, 2022 | americanbankingnews.com
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Short Interest Update
November 13, 2022 | finanznachrichten.de
Bellicum Pharmaceuticals, Inc.: Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
November 10, 2022 | finance.yahoo.com
Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
October 4, 2022 | finance.yahoo.com
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
September 15, 2022 | seekingalpha.com
BLCM Bellicum Pharmaceuticals, Inc.
September 1, 2022 | finance.yahoo.com
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 25, 2022 | finance.yahoo.com
Bellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock Now
August 18, 2022 | finance.yahoo.com
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
August 11, 2022 | finance.yahoo.com
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
May 13, 2022 | seekingalpha.com
Bellicum Pharmaceuticals GAAP EPS of -$0.25 beats by $0.42
May 13, 2022 | finance.yahoo.com
Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update
March 24, 2022 | finance.yahoo.com
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
February 16, 2022 | benzinga.com
Ladenburg Thalmann Initiates Coverage On Bellicum Pharmaceuticals with Buy Rating, Announces Price Target of $5
January 26, 2022 | finance.yahoo.com
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
December 13, 2021 | finance.yahoo.com
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
December 10, 2021 | finance.yahoo.com
Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021
December 7, 2021 | msn.com
Bellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer Studies
December 6, 2021 | markets.businessinsider.com
Bellicum Reports Positive Interim Data From Phase 1/2 GoCAR-T Trials - Quick Facts
December 6, 2021 | finance.yahoo.com
Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market
December 2, 2021 | bizjournals.com
K2 BioLabs hiring, expanding contract research offerings for biotech, pharma startups
November 4, 2021 | finance.yahoo.com
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
September 3, 2021 | finance.yahoo.com
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 1, 2021 | finance.yahoo.com
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
August 12, 2021 | finance.yahoo.com
Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update
See More Headlines
Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BLCM Company Calendar

Last Earnings
8/11/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/23/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLCM
CUSIP
N/A
CIK
1358403
Web
www.bellicum.com
Phone
(832) 384-1100
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+400.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-9,700,000.00
Net Margins
N/A
Pretax Margin
-1,082.27%
Return on Equity
-140.56%
Return on Assets
-55.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.44
Quick Ratio
5.44

Sales & Book Value

Annual Sales
$6.20 million
Price / Sales
1.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.90 per share
Price / Book
0.34

Miscellaneous

Outstanding Shares
8,613,000
Free Float
7,726,000
Market Cap
$8.61 million
Optionable
Optionable
Beta
1.24

Key Executives

  • Mr. Richard A. Fair (Age 53)
    Pres, CEO & Director
    Comp: $915.28k
  • Ms. Charity D. Scripture M.S. (Age 47)
    Pharm.D., Chief Devel. Officer
    Comp: $226.23k
  • Mr. Charles S. Grass (Age 62)
    Principal Accounting Officer
  • Mr. Joseph Senesac (Age 52)
    Sr. VP of Technical Operations & Quality
  • Dr. Alan K. Smith Ph.D. (Age 64)
    Chief Scientific Officer
  • Dr. Aaron E. Foster (Age 49)
    Head of Research & Sr. VP

Key Competitors

View All Competitors













BLCM Stock - Frequently Asked Questions

Should I buy or sell Bellicum Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLCM shares.
View BLCM analyst ratings or view top-rated stocks.

What is Bellicum Pharmaceuticals' stock price forecast for 2023?

1 equities research analysts have issued 12 month target prices for Bellicum Pharmaceuticals' shares. Their BLCM share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 395.0% from the stock's current price.
View analysts price targets for BLCM or view top-rated stocks among Wall Street analysts.

How have BLCM shares performed in 2022?

Bellicum Pharmaceuticals' stock was trading at $1.49 on January 1st, 2022. Since then, BLCM stock has decreased by 32.2% and is now trading at $1.01.
View the best growth stocks for 2022 here.

Are investors shorting Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 129,300 shares, a drop of 7.1% from the October 31st total of 139,200 shares. Based on an average daily trading volume, of 14,300 shares, the days-to-cover ratio is presently 9.0 days.
View Bellicum Pharmaceuticals' Short Interest.

When is Bellicum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our BLCM earnings forecast.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) released its earnings results on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($1.37) by $1.15. The biopharmaceutical company earned $0.70 million during the quarter.

When did Bellicum Pharmaceuticals' stock split?

Bellicum Pharmaceuticals's stock reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), TransEnterix (TRXC), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellicum Pharmaceuticals' stock price today?

One share of BLCM stock can currently be purchased for approximately $1.01.

How much money does Bellicum Pharmaceuticals make?

Bellicum Pharmaceuticals (NASDAQ:BLCM) has a market capitalization of $8.70 million and generates $6.20 million in revenue each year. The biopharmaceutical company earns $-9,700,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The official website for the company is www.bellicum.com. The biopharmaceutical company can be reached via phone at (832) 384-1100 or via email at robert.uhl@westwicke.com.

This page (NASDAQ:BLCM) was last updated on 12/9/2022 by MarketBeat.com Staff